@article{6a9d6d0a8ac74bd188aee20fa849ecc4,
title = "From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm",
abstract = "Precision medicine has exploited next-generation sequencing (NGS) and gene/immune-targeted drug deployment to transform the outlook for several lethal cancers. For instance, there are now several FDA-approved medications that target the sequelae of aberrant genes in a tissue-agnostic approach: pembrolizumab [microsatellite instability and tumor mutational burden (TMB) ≥10 mutations/megabase (mut/Mb)] and larotrectinib/entrectinib (NTRK fusions). Molecular interrogation further reveals the disruptive reality that metastatic cancers are tremendously complex and individually distinct. Therefore, optimized treatment often requires drug combinations (rather than monotherapy) and N-of-one customization. Early studies of this approach suggest feasibility, safety, and efficacy. Real-world data/master registry trials may also provide massive, clinically relevant datasets that further fuel the (r)evolution in oncology.",
keywords = "cancer genes, cell-free DNA, circulating tumor DNA, next-generation sequencing, precision oncology",
author = "Adashek, {Jacob J.} and Vivek Subbiah and Razelle Kurzrock",
note = "Funding Information: Funded in part by the Joan and Irwin Jacobs Fund and by National Cancer Institute grants P30 CA023100 (R.K.). Funding Information: V.S. has research funding/grant support for clinical trials: Novartis, Bayer, GlaxoSmithKline, Nanocarrier, Vegenics, Celgene, Northwest Biotherapeutics, Berghealth, Incyte, Fujifilm, Pharmamar, D3, Pfizer, Multivir, Amgen, Abbvie, Alfa-Sigma, Agensys, Boston Biomedical, Idera Pharma, Inhibrx, Exelixis, Blueprint Medicines, Loxo Oncology, Medimmune, Altum, Dragonfly Therapeutics, Takeda and Roche/Genentech, National Comprehensive Cancer Network , NCI-CTEP, and UT MD Anderson Cancer Center . Travel: Novartis, Pharmamar, ASCO, ESMO, Helsinn, Incyte. US FDA Consultancy/Advisory board: Helsinn, LOXO Oncology/Eli Lilly, R-Pharma US, Incyte, QED Pharma, Medimmune, Novartis. R.K. has research funding from Incyte, Genentech, Merck Serono, Pfizer, Sequenom, Foundation Medicine, Guardant Health, Grifols, Boehringer Ingelheim, and Konica Minolta as well as consultant and/or speaker fees from LOXO, X-Biotech, Actuate Therapeutics, Genentech, Pfizer, Roche, and NeoMed. R.K. has an equity interest in IDbyDNA and Curematch, Inc. and is Board Member of CureMatch and CureMetrix and cofounder of CureMatch.",
year = "2021",
month = jan,
doi = "10.1016/j.trecan.2020.08.009",
language = "English (US)",
volume = "7",
pages = "15--28",
journal = "Trends in Cancer",
issn = "2405-8033",
publisher = "Cell Press",
number = "1",
}